PURA - Puration Confirms Spinoff Scheduled Next Week and Announces New Target Cannabis Beverage Acquisition

PURA - Puration Confirms Spinoff Scheduled Next Week and Announces New Target Cannabis Beverage Acquisition

Dallas, TX -- September 28, 2018 -- InvestorsHub NewsWire -- Puration, Inc. (USOTC: PURA) (“PURA”) today confirmed the company plans to execute a definitive transaction by next Thursday, the 6^th of October with Nouveau Life Pharmaceuticals, Inc., (USOTC: NOUV) (“NOUV”).  The transaction is designed to affect a “spinoff” of PURA’s cannabis cultivation business with shares of NOUV being issued to PURA shareholders in a stock dividend.  The spinoff is part of a strategy for PURA to focus all resources on expanding its cannabis infused beverage business.  PURA introduced EVERx CBD Sports Water last year and company sales have since increased 600%.  In addition to expanding and growing its cannabis beverage business organically, PURA plans to acquire additional beverage businesses as well.  Today the company is announcing a first target acquisition is in the works.  The target acquisition is anticipated to be announced shortly after the closing of the spinoff transaction.

Learn more about Puration at www.purationinc.com
Learn more about the cultivation business at  https://www.purationinc.com/extraction
Disclaimer/Safe Harbor: 

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. 

Puration, Inc.
Brian Shibley,
[e-mail]
[phone]